Intellia Therapeutics (NTLA) Other financing activities (2017 - 2025)

Intellia Therapeutics (NTLA) has reported Other financing activities for 9 consecutive years, with $625000.0 the latest figure, recorded in Q4 2025.

• In Q4 2025, Other financing activities fell 52.54% year-over-year to $625000.0; the TTM figure through Dec 2025 stood at $722000.0 (down 75.82% YoY), while the FY2025 annual figure was $722000.0, down 75.82% from the prior year.
• Other financing activities advanced to $625000.0 in Q4 2025 per NTLA's latest filing, from -$1.1 million in the prior quarter.
• Across five years, Other financing activities topped out at $39.7 million in Q3 2021 and bottomed at -$13.1 million in Q2 2021.
• Historically, Other financing activities has averaged $3.5 million across 5 years, with a median of $1.2 million in 2021.
• On a YoY basis, Other financing activities climbed as much as 3870.24% in 2021 and fell as far as 3862.75% in 2021.
• Intellia Therapeutics' Other financing activities stood at $1.2 million in 2021, then jumped by 996.98% to $13.4 million in 2022, then plunged by 86.04% to $1.9 million in 2023, then slipped by 29.87% to $1.3 million in 2024, then slumped by 52.54% to $625000.0 in 2025.
• Business Quant data shows NTLA's Other financing activities at $625000.0 in Q4 2025, -$1.1 million in Q3 2025, and $1.2 million in Q2 2025.